February 7th 2025
There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results suggest ifetroban may improve left ventricular ejection fraction in patients with DMD.
Smartphone Tech Reveals Gait Differences in Duchenne Muscular Dystrophy
FDA Extends Review Time for Investigational Duchenne Agent Givinostat
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies